title: Clinical correlates of sleep benefit in Parkinson's disease.
abstract: The phenomenon of sleep benefit, a period of lessened disability or feeling "on" upon awakening from sleep in the morning, has received scant attention in the literature on Parkinson's disease. We interviewed 162 consecutive patients regarding disease onset, medication history, and symptoms, evaluated them using the Unified Parkinson's Disease Rating Scale, and assessed them as to the presence or absence of sleep benefit. Thirty-three percent reported experiencing sleep benefit. Compared with patients not having sleep benefit, patients with sleep benefit tended to be younger at disease onset, have longer disease duration, take higher total daily doses of levodopa, have longer duration of levodopa treatment, and exhibit less cognitive and physical disability. The findings of this study suggest that sleep benefit is a common phenomenon that may be anticipated in a subgroup of patients with Parkinson's disease. The mechanisms underlying sleep benefit do not appear to be simple and may be multifactorial. Clinicians need to be aware of the authenticity of patients' reports of sleep benefit and consider the existence of this phenomenon when prescribing or adjusting patients' medication schedules.
authors.affiliation: Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
authors.forename: L J
authors.initials: LJ
authors.lastname: Currie
authors.forename: J P
authors.initials: JP
authors.lastname: Bennett
authors.forename: M B
authors.initials: MB
authors.lastname: Harrison
authors.forename: J M
authors.initials: JM
authors.lastname: Trugman
authors.forename: G F
authors.initials: GF
authors.lastname: Wooten
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D002415:Cats; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D012720:Severity of Illness Index; D012890:Sleep / Q000502:physiology*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D007980:Levodopa